[Effect of amantadine or 3-cyclopentyl adamantanamine on the immobility of adult or aged mice, in the forced swim test].
Amantadine (AMA), an antiparkinsonian drug, (20 mg/Kg, ip) or 3-cyclopentyl adamantanamine (AdCP), an AMA derivative synthesized recently, (20 mg/Kg, ip) induced an anti-immobility effect-comparable to those of imipramine (IMI), an antidepressive drug, (30 mg/Kg, ip) - in the forced swim test (FST), on adult (4 months) Balb-C mice. In contrast, on aged (10 months) Balb-C mice, only AdCP (20 or 40 mg/Kg, ip) was active in the FST. It is suggested that the inactivity of AMA or IMI on the aged Balb-C mice could be the consequence of their NMDA (i.e., N-methyl-D-aspartic acid sensitive) receptors failure. This NMDA receptors dysfunction could render non significant the antagonism of the mice immobility in the FST, induced by AMA or IMI, which could result (in part for IMI) from the anti-NMDA effect of these drugs. In contrast AdCP, which may principally act by glycinergic A (strychnine sensitive) effect, inhibiting the release of the brain monoamines and glutamate, conserved its activity in the FST on aged mice. In conclusion, it seems that the neurochemical profile of the drugs studied in the FST, could be useful for understanding their anti-immobility effect and for a rational approach of their possible clinical use as antidepressant.